论文部分内容阅读
肿瘤治疗已经进入分子靶向治疗时代,抗血管新生治疗是靶向治疗的重要策略,在肿瘤多学科综合治疗中发挥着非常重要的作用。本文就近年来肿瘤抗血管新生治疗过程中发现的与疗效评价、抵抗性相关的生物标志物作一综述,旨在为抗血管新生治疗的疗效评价和实现肿瘤的个体化治疗提供理论依据。
Tumor therapy has entered the era of molecular targeted therapy. Antiangiogenic therapy is an important strategy of targeted therapy and plays a very important role in the multidisciplinary treatment of tumors. This review summarizes biomarkers related to efficacy evaluation and resistance found in the course of antiangiogenic therapy in recent years and aims to provide a theoretical basis for evaluating the curative effect of antiangiogenic therapy and realizing individualized treatment of tumors.